ESI-GROUP/FAW-VW
2.4.2024 08:01:33 CEST | Business Wire | Press release
Regulatory News:
ESI Group (Paris:ESI) and FAW-Volkswagen (FAW-VW) TE have commemorated their strategic partnership with the signing of a Memorandum of Understanding (MoU) aimed at advancing intelligent simulation technology within the automotive industry. The ceremony, held at the FAW-VW R&D center in Changchun, Jilin Province, PRC, was officiated by Deng Guohui, Technical Development Director at FAW-VW, and Francis Griffiths, Executive Vice-President and Chief Revenue Officer at ESI Group.
The collaboration between ESI Group and FAW-VW TE aims to address the challenges posed by China's automotive safety regulations and drive industry innovation. Through this partnership, the two entities will aim to drive innovation and efficiency in intelligent simulation, and work towards establishing a localized automotive industry material database, thereby enhancing cooperation in advancing intelligent simulation technology across the industry. This collaborative effort is geared toward paving the way for a cleaner, safer, and more productive future.
Under the MoU, a material testing and intelligent simulation joint laboratory has been established, marking a significant step forward in intelligent simulation, innovation, and research within the automotive sector.
“With over 40 years of collaboration, ESI Group and VW Group have built strong ties, including a fruitful partnership with FAW-VW since 2007. This marks a significant milestone in our commitment to advancing virtual simulation technology in the automotive sector. Together with FAW-Volkswagen, we aim to drive innovation and efficiency in intelligent simulation, materials research and development,” declared Francis Griffiths, Executive Vice-President, Chief Revenue Officer at ESI Group.
"Today's milestone event celebrates not only two decades of fruitful collaboration but also embarks on a new era of innovation in automotive virtual simulation with ESI. This partnership signifies more than a formal agreement; it is a testament to our shared vision and commitment, aiming to pioneer intelligent simulation and materials research, setting new industry standards, and driving automotive safety and efficiency forward." declared Deng Guohui, Technical Development Director at FAW-VW.
During the ceremony, FAW-VW TE and ESI Group exchanged awards to honor their collaborative achievements in innovation. FAW-VW TE awarded ESI Group the prestigious "CAE Trusted Advisor" award, recognizing ESI's outstanding support in advancing virtual simulation technology in the automotive industry.
ESI Group reciprocated by presenting multiple global awards to FAW-VW's Technology Development team, including "Best Cooperation Partner" represented by Deng Guohui, Technical Development Director at FAW-VW and "Best Simulation Method Development Team" represented by Fu Xiaolong. Li Dapeng was also honored with the "'Virtual Performance Expert" award for their exceptional contributions. These accolades underscore the mutual respect, shared goals, and commitment of both companies to advancing automotive safety and efficiency through successful collaboration.
About ESI Group
ESI Group, a part of Keysight Technologies, provides reliable and customized solutions anchored on predictive physics modeling and virtual prototyping expertise. Acting principally in automotive, land transportation, aerospace and defense, and heavy industry, ESI software enables engineers to simulate mechanical designs, smart manufacturing processes, and human-centric workflows to make better decisions earlier in the product lifecycle. Keysight is an S&P 500 company delivering market-leading design, emulation, and test solutions to help engineers develop and deploy faster, with less risk, throughout the entire product lifecycle. For further information, go to: www.esi-group.com
Follow ESI LinkedIn | Facebook | Twitter | YouTube
About FAW-Volkswagen
Established on February 6, 1991, FAW-Volkswagen Automotive Co., Ltd. (hereinafter referred to as FAW-Volkswagen) is a large-sized passenger auto manufacturer jointly managed by First Automotive Group Corporation, Volkswagen AG, Audi AG and Volkswagen (China) Investment Co., Ltd. It is the domestic first modern passenger auto manufacturer constructed according to the economic scale.
Through the development of around 30 years, FAW-Volkswagen has had the capacity layout in Changchun in the Northeast, Chengdu in the Southwest, Foshan in South China, Qingdao in East China and Tianjin in North China. It boasts eight professional manufacturing factories, namely No. 1 Car Factory, No. 2 Car Factory, No. 3 Car Factory, No. 4 Car Factory, No. 5 Car Factory, No. 6 Car Factory, Business Division of Power Assembly, and Punching Center.
Add: No. 5 Anqing Road, Auto Industry Development District, Changchun Jilin Province, PRC
To view this piece of content from cts.businesswire.com, please give your consent at the top of this page.
View source version on businesswire.com: https://www.businesswire.com/news/home/20240401600103/en/
About Business Wire
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
Backed by Investments Exceeding $1 Billion, PCI Pharma Services Announces Major Expansion of US Sterile Fill-Finish and Drug-Device Delivery Combination Capabilities27.4.2026 16:00:00 CEST | Press release
As pharma manufacturers prioritize US supply chain resilience, highlights include high-speed isolator filling lines for prefilled syringes, cartridges and vials, and drug-device combination assembly and packaging. PCI Pharma Services (“PCI”) – a world-leading integrated global contract development and manufacturing organization (CDMO) focused on innovative biologic and small molecule therapies – announced a series of major infrastructure investments that substantially deepen its sterile fill-finish and advanced drug delivery capabilities. As pharma manufacturers and their development partners increasingly prioritize US supply chain resilience, PCI’s latest investments come as part of a broader commitment exceeding $1 billion across the CDMO’s US and European operations, reinforcing its ability to provide seamless support for drug product development and manufacturing, clinical trial supply and drug-device combination assembly from clinical stages through commercial launch – all underpi
Pure Lithium Appoints Renowned Battery Expert Dr. Yuan Gao to Board of Directors27.4.2026 15:53:00 CEST | Press release
Pure Lithium Corporation, a vertically integrated lithium metal battery technology company, is pleased to announce that world-renowned inventor and battery expert Dr. Yuan Gao has joined the company’s Board of Directors. Dr. Gao has been an invaluable member of Pure Lithium’s Scientific Advisory Board since October of 2023. "We are thrilled to have Dr. Gao join our board as we focus on rapidly scaling our technology in the most capital efficient manner possible,” said Pure Lithium Founder, Chairman and CEO Emilie Bodoin. “Dr. Gao is a brilliant scientist who also has deep commercial expertise, a rare combination. He is also unique in the industry because his experience spans the entire battery materials value chain, including all of Pure Lithium’s verticals. His insights over the years have been critical in advancing our technology, and his experience as a director of public companies will strengthen our board.” Dr. Gao commented: “I am thrilled to join the board of Pure Lithium Corpor
Taiho Oncology, Taiho Pharmaceutical and Araris Biotech AG Advance ADC ARC-02 into Phase 1 Clinical Development27.4.2026 15:00:00 CEST | Press release
Phase 1 dose-escalation trial represents the first clinical trial of a product developed using the AraLinQ™ ADC technology and marks Taiho’s expansion into the clinical development of ADCs for oncology Taiho Oncology, Inc., Taiho Pharmaceutical Co., Ltd., and Araris Biotech AG (“Araris”) today announced that the U.S. Food and Drug Administration (FDA) has completed its Investigational New Drug (IND) review period for ARC-02, an antibody-drug conjugate (ADC) being developed for the treatment of non-Hodgkin lymphoma, enabling Taiho Oncology to initiate a Phase 1 dose-escalation clinical trial of ARC-02. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260427127507/en/ Taiho Pharmaceutical acquired Araris Biotech in March 2025, expanding Taiho group’s capabilities in biologics and ADC research and development. Araris is a spin-off of the Paul Scherrer Institute and ETH in Switzerland focused on the development of antibody-drug co
Boomi To Unveil the Future Of Data Activation and AI-Driven Innovation at Boomi World 202627.4.2026 15:00:00 CEST | Press release
Premier global event to highlight how organizations are bringing data to life to power everything from AI to BI Boomi, the data activation company, today announced Boomi World 2026, its premier annual user conference, taking place May 11 - 14, 2026 in Chicago, IL. The event will bring together customers, partners, and industry leaders from around the world to explore how data activation is transforming the enterprise and accelerating the path to AI-driven outcomes. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260427600340/en/ Boomi To Unveil the Future Of Data Activation and AI-Driven Innovation at Boomi World 2026 Boomi World 2026 will spotlight data activation — bringing data to life to power AI, analytics, and intelligent automation. Attendees will gain firsthand insights into how the Boomi Enterprise Platform enables businesses to unify data, streamline operations, and innovate faster in an increasingly agentic world.
Axinn Appoints Rachael Philbin as Chief Innovation Officer27.4.2026 15:00:00 CEST | Press release
Appointment Reflects Firm's Vision for the Future of Legal Practice Axinn, Veltrop & Harkrider LLP today announced the appointment of Rachael Philbin as Chief Innovation Officer, reinforcing the firm’s continued investment in advanced solutions and technology for legal services delivery. Philbin joins from Proskauer Rose LLP, where she served as Innovation & Transformation Officer. Based in Axinn's New York office, she will lead the firm’s AI and legal technology initiatives as well as knowledge management efforts, accelerating adoption and integration across its antitrust, intellectual property, and litigation practices. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260427277725/en/ Rachael Philbin joins Axinn, Veltrop & Harkrider LLP as Chief Innovation Officer. “As Axinn continues to grow, we are making deliberate investments in the capabilities that enable our lawyers to deliver service and results at the highest level
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom